NICE and NOGG recommendations
NICE 2022 recommendation5
EVENITY is recommended as an option for treating severe osteoporosis in people after menopause who are at high risk of fracture, only if:
- They have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture)
- The company provides EVENITY according to the commercial arrangement
NOGG/ROS Advisory statement on the prioritisation of romosozumab in clinical practice6
Referral for, and consideration of treatment with EVENITY, is prioritised in postmenopausal women who have had a MOF within 24 months, with any one of the following:
- A BMD T-Score ≤-3.5 (at the hip or spine)
- A BMD T-score ≤-2.5 (at the hip or spine
- Vertebral fractures (either a vertebral fracture within 24 months or a history of ≥2 osteoporotic vertebral fractures)
- Very high fracture risk (e.g., as quantified by FRAX)
Following the approved duration of treatment with EVENITY (12 months), treatment with alendronate, zoledronate or denosumab should be initiated without delay.
What’s behind EVENITY
From the frontiers of space to the front line of fracture treatment. Watch our short film to discover exactly how EVENITY became reality.
- EVENITY SmPC.
- Cosman F, et al. N Engl J Med 2016;37S:S132-1S43.
- Rosen CJ. N Engl J Med 2017:37:71479-1480.
- Ferrari SL. Nat Rev Rheumatol 2018;14:128.
- NICE. NICE Technology Appraisal Guidance — Romosozumab for treating severe osteoporosis. TA791. 25 May 2022. Available at:
https://www.nice.org.uk/guidance/TA791. Accessed December 2022.
- NOGG. Consensus Advisory Statement from the National Osteoporosis Guideline Group (NOGG) and Royal Osteoporosis Society (ROS) on the use of romosozumab, following the 2022 NICE Appraisal. 30 May 2022. Available at:
https://strwebprdmedia.blob.core.windows.net/media/Oh3jlogS/nogg-ros-romosozumab-statement-may-2022.pdf. Accessed December 2022.
- Saag K, et al. N Eng J Med 2017;377:1417-1427.
- Langdahl BL, et al. Lancet 2017;390:1585-1594.
- Toth E, et al. Osteoporos Int 2018 Apr;29(Suppl 1):149-565.
- Van Geel TA, et al. Ann Rheum Dis 2009:68:99-102.